Current FDA approved PD-L1 inhibitors include avelumab, durvalumab, and atezolizumab for specific uses in advanced urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer (NSCLC), among others (46). The gene discussed is CD274; the disease is urothelial carcinoma.